There are 3484 resources available
Advances in ADCs for Head and Neck Cancer
Presenter: Laura Locati
Session: Seagen - ADCs’ Potential Across Tumors
Resources:
Webcast
Targeting molecular aberrations beyond EGFR, ALK: Clinical evidence for efficacy and ongoing research
Presenter: Jürgen Wolf
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Slides
Webcast
The utility of HRD testing – current status and future trends
Presenter: All Speakers
Session: Illumina - Detection of homologous recombination deficiency (HRD): Role of HRD testing and impact on patient management
Resources:
Webcast
Q&A and discussion
Presenter: All Speakers
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Webcast
Future Directions for ADCs in Urothelial Cancer
Presenter: Thomas Powles
Session: Seagen - ADCs’ Potential Across Tumors
Resources:
Webcast
Closing remarks
Presenter: Frederique Penault-Llorca
Session: Illumina - Detection of homologous recombination deficiency (HRD): Role of HRD testing and impact on patient management
Panel Discussion and Audience Q&A
Presenter: All Speakers
Session: Seagen - ADCs’ Potential Across Tumors
Resources:
Webcast
Concluding remarks
Presenter: Jürgen Wolf
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Webcast
Closing Remarks
Presenter: Josep Tabernero
Session: Seagen - ADCs’ Potential Across Tumors
Resources:
Webcast
Welcome and “set the scene”
Presenter: Elena Castro
Session: PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor: One approach for all
Resources:
Slides
Webcast